Browse the evidence

AgRP neuron inhibition is a necessary mechanism for the appetite-suppressing effects of incretin-based obesity therapies (GLP-1 and GIP analogs).

This research confirms that GLP-1 and GIP medications (like Ozempic or Wegovy) work by directly inhibiting the brain's hunger-promoting neurons (AgRP). This neural inhibition is a key reason these drugs successfully suppress appetite.

GIP signaling is necessary for nutrient-mediated inhibition of AgRP neurons, whereas GLP-1 signaling is not.

This study reveals that GIP, not just GLP-1, is essential for your brain to register that you have eaten. This explains why drugs that activate both receptors (like Mounjaro/Zepbound) may be more effective than those activating only GLP-1.

GIPR signaling in the central nervous system (specifically GABAergic neurons) is required for the body weight-lowering effects of GIP-based therapies, whereas peripheral GIPR signaling in adipose tissue has complex, context-dependent effects on lipolysis vs lipogenesis.

GIP-based drugs work primarily by acting on the brain to reduce food intake, not just by affecting fat cells. This brain-based mechanism is why they are effective for weight loss even in non-diabetic individuals.

Lifelong endurance training preserves skeletal muscle oxidative capacity and capillarization in men aged 82-92, whereas physical function level does not correlate with these morphological markers.

For men in their 80s, maintaining a history of endurance training is associated with better muscle blood supply and energy production than simply being strong. While you cannot change your past, the data suggests that consistent aerobic activity preserves muscle quality better than inactivity, regardless of current strength levels.

Endurance training does not preserve satellite cell numbers or markers of muscle regeneration/denervation in very old men compared to sedentary peers.

Do not expect exercise to restore youthful muscle repair capabilities (satellite cells) in your 80s. While training improves blood flow and energy use, the cellular machinery for regeneration appears to decline with age regardless of activity level.

Dietary macronutrient composition (low-carbohydrate vs. low-fat) does not explain differences in ad libitum energy intake because the resulting changes in gut-derived appetite hormones (GLP-1, GIP, PYY, ghrelin) are insufficient to override other dietary factors like energy density and hyper-palatability.

Don't rely on low-carb or low-fat diets to magically regulate your hunger through hormones. This study shows that even when hormones change significantly, they don't dictate how much you eat if other factors like energy density and taste are present. Focus on the physical properties of food (volume, density) rather than just the macronutrient ratio for short-term intake control.

GLP-1 administration (25 nmol/kg) significantly augments glucose-stimulated insulin secretion and improves glucose tolerance in mice, whereas GLP-2 (25 nmol/kg) improves glucose tolerance without directly augmenting insulin secretion.

Both GLP-1 and GLP-2 peptides improve blood glucose levels in mice, but they do so through different biological pathways. GLP-1 works by telling beta cells to release more insulin, while GLP-2 improves glucose handling without directly increasing insulin secretion. This suggests that targeting GLP-2 receptors could be a viable strategy for glucose control that avoids potential side effects of excessive insulin secretion.

Both GLP-1 and GLP-2 suppress appetite and reduce food intake in mice, regardless of their differential effects on insulin secretion.

Both GLP-1 and GLP-2 peptides reduce food intake in mice, suggesting that GLP-2 could be used to manage appetite without necessarily stimulating insulin secretion. This makes GLP-2 a potential candidate for obesity treatment where insulin secretion is not desired.

Both GLP-1 and GLP-2 promote beta-cell proliferation and protect against cytokine-induced apoptosis, preserving beta-cell mass and function.

Both GLP-1 and GLP-2 help protect beta-cells from death and promote their growth. This suggests that GLP-2 could be used to preserve beta-cell mass in diabetes, potentially slowing disease progression.

Naltrexone/Bupropion is not recommended for individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) due to potential hemodynamic stress and lack of outcome data.

If you have obesity and established heart disease or heart failure, naltrexone/bupropion is not recommended because it can increase heart rate and blood pressure, potentially worsening your condition. Safer, proven alternatives are available.

Semaglutide, despite achieving NASH resolution, failed to improve fibrosis stage in phase 2 trials, highlighting a gap in treating advanced fibrosis compared to resmetirom.

Semaglutide helps resolve NASH but does not improve fibrosis. Patients with advanced fibrosis should consider other options like resmetirom.

Obeticholic acid (OCA) trials for NASH were discontinued due to safety concerns and modest efficacy, despite showing some histological improvement.

Obeticholic acid is not approved for NASH due to safety issues.

Lixisenatide and high-dose efpeglenatide (6 mg/week) are associated with a statistically significant increase in hearing loss events compared to controls, whereas other GLP-1 receptor agonists and SGLT2 inhibitors do not demonstrate this elevated risk.

If you are taking Lixisenatide or high-dose Efpeglenatide, be aware of a potential increased risk of hearing loss. This risk is not seen with other GLP-1 drugs like Semaglutide or Dulaglutide in this analysis. Report any sudden hearing changes to your doctor immediately, but do not stop your medication without consulting them, as the absolute risk (NHH ~757) is relatively low.

Current randomized controlled trials of nutrient-stimulated hormone-based therapies (NuSHs) for obesity predominantly fail to assess nutritional and functional outcomes, focusing almost exclusively on body weight.

If you are participating in or designing a NuSH trial, you must include nutritional and functional assessments (body composition, muscle strength, bone health) alongside weight. Relying solely on weight masks potential risks like sarcopenia and bone loss.

Current NuSH trials rarely assess bone health, despite the known risk of bone mass reduction associated with significant weight loss.

If you are on NuSHs, ask your doctor about bone density scans, especially if you are post-menopausal or elderly. Ensure adequate calcium and vitamin D intake, as weight loss can compromise bone strength.

Obesity (BMI ≥30 kg/m2) significantly increases annual health care resource utilization (HCRU) and causes substantial premature mortality, resulting in billions of pounds in lifetime economic loss and quality-adjusted life year (QALY) deficits.

Obesity imposes a massive financial and health burden on society, costing billions in healthcare resources and causing significant premature death. While losing weight reduces annual healthcare costs, the benefit is largely negated by the increased life expectancy of formerly obese individuals, meaning the total lifetime cost remains high. Public health policy must account for this lifetime cost, not just short-term annual savings.

Socioeconomic deprivation is strongly correlated with higher prevalence of obesity (BMI ≥40) and higher mortality rates, with the most deprived areas facing the greatest healthcare burden.

Obesity and its associated health risks are significantly higher in socioeconomically deprived areas. Public health interventions should target these areas, as they bear the greatest burden of obesity-related mortality and healthcare costs.

Biological mechanisms, specifically a defended weight set point driven by genetic and epigenetic factors, actively oppose weight loss maintenance by altering hunger hormones and reducing energy expenditure, making long-term weight loss difficult without continuous intervention.

Accept that maintaining weight loss is biologically harder than losing it due to hormonal defenses. Do not rely on short-term diets; instead, focus on long-term strategies like preventing 'weight creep' (0.5-1kg/year gain) through low-intensity lifestyle changes or considering long-term pharmacological support (like GLP-1 agonists or metformin) if indicated, rather than expecting a one-time fix.

Protein restriction (specifically low-protein, high-carbohydrate diets) extends lifespan and improves metabolic health in model organisms, likely through mechanisms distinct from or overlapping with calorie restriction, such as elevated FGF21.

In model organisms, restricting protein (while keeping calories normal) extends lifespan and improves metabolic health, partly by boosting FGF21. However, this comes at the cost of muscle mass. For humans, high protein is generally recommended for muscle maintenance, but excessive intake might increase mortality risk. The optimal protein intake likely balances longevity benefits with the need to preserve physical resilience, suggesting a moderate approach rather than extreme restriction or excess.

Chronic chicken meat intake and resistance training do not drastically alter gut microbiota composition in elderly women, contradicting hypotheses that such interventions significantly shift microbial diversity.

You do not need to worry about chicken meat or resistance training negatively impacting or drastically altering your gut microbiota in a harmful way. The study found no significant changes in gut bacteria diversity, suggesting these interventions are safe for gut health in this demographic.

Under volume-matched conditions, increasing resistance training frequency from two to four sessions per week does not result in greater maximal strength gains in trained men.

If you are a trained lifter, you do not need to train every muscle group 4 times a week to maximize strength. Training 2 times per week is equally effective for strength gains as training 4 times per week, provided you perform the same total number of sets and intensity. You can choose the frequency that best fits your schedule and recovery capacity without sacrificing strength gains.

Intensive lifestyle intervention for weight loss in type 2 diabetes does not significantly reduce the primary composite cardiovascular endpoint (death from CV causes, nonfatal MI, nonfatal stroke, or hospitalization for angina) compared to diabetes support and education.

For people with type 2 diabetes, intensive lifestyle changes (diet and exercise) aiming for modest weight loss (7%) and activity (175 mins/week) did not statistically reduce the combined risk of heart attack, stroke, or CV death compared to standard support. However, achieving larger weight loss (10%+) and improved fitness was associated with reduced risk of CV death and major cardiac events. Continue lifestyle efforts for overall health and specific risk reduction, even if the broad 'heart attack prevention' claim is statistically unproven in this specific trial design.

Individuals with greater personal success in weight loss without medication exhibit higher obesity stigma and less favorable attitudes toward anti-obesity medications.

Healthcare providers should recognize that patients who have successfully lost weight through diet and exercise may be skeptical of or stigmatizing toward GLP-1 medications. Counseling should validate their success while explaining that biological factors can persist despite lifestyle efforts, making medication a valid and effective tool for others.

Male sex, older age (≥65 years), lower socioeconomic status (lower income, less education, higher area deprivation), and lack of insurance are associated with significantly lower odds of receiving anti-obesity medication (AOM) prescriptions and metabolic and bariatric surgery (MBS).

If you are male, older, or have limited income/insurance, you face significant systemic barriers to accessing obesity treatments like GLP-1s or surgery. This is not a reflection of your medical need but of socio-economic disparities. Seek providers who are aware of these disparities and advocate for coverage options or financial assistance programs.